Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma

Chin Med J (Engl). 2012 Jun;125(12):2231-4.

Abstract

Sporadic malignant pheochromocytoma, a rare disease with poor prognosis, is always difficult to treat due in part to lack of effective agents. We presented three patients with advanced malignant pheochromocytoma treated by sunitinib, which indicates that sunitinib is an effective agent for this malignancy.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Gland Neoplasms / drug therapy*
  • Adult
  • Female
  • Humans
  • Indoles / therapeutic use*
  • Male
  • Middle Aged
  • Pheochromocytoma / drug therapy*
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrroles / therapeutic use*
  • Sunitinib

Substances

  • Indoles
  • Protein Kinase Inhibitors
  • Pyrroles
  • Sunitinib